Related Experiment Video

Updated: Jun 20, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer

Yu-Zhou Huang1, Ming-Yi Sang1, Pei-Wen Xi2

  • 1Jiangsu Breast Disease Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, PR China.

Cancer Research
|July 22, 2024
PubMed

Insights

Targeting FANCI protein can improve breast cancer treatment with PARP inhibitors, even in tumors without BRCA mutations. This approach enhances drug efficacy and offers new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer poses a significant global health challenge, driving the need for novel therapeutic strategies.
  • Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in specific breast cancer subtypes, primarily those with homologous recombination deficiency.
  • Current limitations in PARP inhibitor application necessitate exploring new therapeutic targets.

Purpose of the Study:

  • To investigate the potential of suppressing FANCI as a strategy to enhance PARP inhibitor efficacy in breast cancer.
  • To determine the association between FANCI expression and breast cancer prognosis, proliferation, and migration.
  • To elucidate the interaction between FANCI and PARP1 and its impact on PARP1 functionality.

Main Methods:

  • Assessed FANCI expression levels in breast cancer tissues and correlated them with patient prognosis.
  • Investigated the physical interaction between FANCI and PARP1 using co-immunoprecipitation assays.
  • Examined the effect of FANCI suppression on the nuclear localization and activity of PARP1.
  • Evaluated the sensitivity of breast cancer cells to the PARP inhibitor talazoparib following FANCI inhibition, with and without BRCA mutations.
  • Assessed the impact of combining palbociclib (a CDK4/6 inhibitor) with talazoparib on breast cancer cells, focusing on FANCI inhibition.

Main Results:

  • Elevated FANCI expression in breast cancer correlated with poorer prognosis, increased cell proliferation, and migration.
  • FANCI was found to interact with PARP1, and its suppression reduced PARP1's nuclear localization and functionality.
  • FANCI inhibition sensitized breast cancer cells to talazoparib, irrespective of BRCA mutation status.
  • The CDK4/6 inhibitor palbociclib enhanced the sensitivity of breast cancer cells to talazoparib by inhibiting FANCI.

Conclusions:

  • Suppression of FANCI represents a viable therapeutic strategy to improve PARP inhibitor efficacy in breast cancer.
  • Targeting FANCI offers a promising approach for enhancing PARP inhibitor sensitivity, potentially expanding treatment options beyond BRCA-mutated cancers.
  • The combination of CDK4/6 inhibitors and PARP inhibitors, mediated through FANCI inhibition, presents a novel therapeutic avenue for breast cancer treatment.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.0K

Related Concept Videos

Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K